SequelSEC

Pyxis Oncology, Inc. PYXS

Pharmaceutical Preparations · CIK 0001782223 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$11.04M
Fiscal year ended 2025-12-31
Operating income
-$18.30M
Fiscal year ended 2025-12-31
Free cash flow
-$10.43M
Fiscal year ended 2025-12-31

Pyxis Oncology, Inc. (PYXS) reported revenue of $11.04M and net income of -$18.11M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Pyxis Oncology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Pyxis Oncology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-31
Revenue$11.04M$0$2.82M$0$0$0$16.15M
Cost of revenueUnavailableUnavailableUnavailable$0$0$0$475.00K
Gross profitUnavailableUnavailableUnavailable$0$0$0$15.67M
Operating income-$18.30M-$23.46M-$19.75M-$40.07M-$23.75M-$20.03M-$5.60M
Net income-$18.11M-$22.00M-$18.35M-$35.57M-$21.20M-$17.30M-$3.26M
Research & development$21.71M$17.81M$17.13M$14.02M$17.74M$13.95M$13.03M
Weighted-average diluted sharesUnavailableshares 62.56Mshares 61.92MUnavailableshares 60.72Mshares 60.50Mshares 51.29M
Pretax income-$17.00M-$22.00M-$18.07M-$37.74M-$21.20M-$17.30MUnavailable
Income tax expense$1.10M$0$283.00KUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.35$-0.30Unavailable$-0.35$-0.29$-0.06
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.23M$5.65M$5.44M$5.08M$6.01M$6.08M$8.25M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Pyxis Oncology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$15.42M$8.92M$10.73M$19.47M$12.06M$25.07M$27.97M
Total assets$91.52M$105.60M$123.22M$157.18M$195.31M$208.39M$220.22M
Current assets$72.10M$83.07M$99.96M$132.44M$148.87M$161.04M$172.38M
Total liabilities$38.11M$36.82M$35.57M$36.43M$41.63M$38.60M$36.06M
Current liabilities$21.13M$19.38M$17.68M$17.68M$20.32M$16.90M$14.14M
Total equity incl. NCI$53.41M$68.78M$87.64M$120.75M$153.68M$169.79M$184.16M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$3.00MUnavailableUnavailableUnavailable$8.00M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$10.88M$9.76M$9.41M$4.86M$4.87M$5.47M$2.29M

Cash flow

Pyxis Oncology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$10.43M-$13.28MUnavailable-$19.29M-$14.66M-$3.01M-$20.71M
Capital expenditures$0UnavailableUnavailable$0$0$0$237.00K
Investing cash flow$16.26M$11.47MUnavailable$26.66M-$8.00K$4.00K-$18.50M
Financing cash flow$669.00K-$8.00KUnavailable$50.00K$1.66M$110.00K$57.51M
Net change in cash$6.50M-$1.81MUnavailable$7.42M-$13.02M-$2.89M$18.30M
Stock-based compensation$2.08M$3.07MUnavailable$2.77M$2.98M$2.87M$4.32M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$2.90M$527.00KUnavailable$550.00K$731.00K$585.00K$1.12M

Derived

Pyxis Oncology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-31
Free cash flow-$10.43MUnavailableUnavailable-$19.29M-$14.66M-$3.01M-$20.95M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable97.1%
Operating margin-165.7%UnavailableUnavailableUnavailableUnavailableUnavailable-34.7%
FCF margin-94.5%UnavailableUnavailableUnavailableUnavailableUnavailable-129.7%
SBC / revenue18.9%UnavailableUnavailableUnavailableUnavailableUnavailable26.8%
Current ratio3.41x4.29x5.65x7.49x7.33x9.53x12.19x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-164.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue196.7%UnavailableUnavailableUnavailableUnavailableUnavailable80.7%
CapEx / revenue0.0%UnavailableUnavailableUnavailableUnavailableUnavailable1.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PYXS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.